Your session is about to expire
← Back to Search
Behavioural Intervention
Tobacco Use Disorder in Smokers With and Without Schizophrenia
N/A
Waitlist Available
Led By Britta Hahn, Ph.D.
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one day (in the ad libitum smoking session), over an 8-hour time frame.
Awards & highlights
No Placebo-Only Group
Summary
This trial looked at how people with schizophrenia perceive cigarette smoking, and how this affects their smoking habits. The findings suggest that people with schizophrenia perceive smoking differently than the general population, which has implications for how we treat them for smoking cessation.
Eligible Conditions
- Tobacco Addiction
- Schizophrenia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one day (in the ad libitum smoking session), over an 8-hour time frame.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one day (in the ad libitum smoking session), over an 8-hour time frame.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Cigarette Discrimination Accuracy
End-of-session Carbon Monoxide
Secondary study objectives
Change in the Number of Research Cigarettes Smoked
Difference in Subjective State Composite Score
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Smokers without schizophreniaExperimental Treatment1 Intervention
This is a diagnostic group (i.e., no diagnosis of schizophrenia), defined independently from this study.
Group II: Smokers with schizophreniaExperimental Treatment1 Intervention
This is a diagnostic group, defined independently from this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sampling Research Cigarettes
2021
N/A
~40
Find a Location
Who is running the clinical trial?
University of Maryland, BaltimoreLead Sponsor
710 Previous Clinical Trials
379,128 Total Patients Enrolled
Britta Hahn, Ph.D.Principal Investigator - University of Maryland, Baltimore
University of Maryland, Baltimore
3 Previous Clinical Trials
95 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have an intellectual disability.You have had a problem with alcohol or drugs, excluding nicotine, in the past year.You have very serious asthma.You have a long-term lung condition called chronic obstructive pulmonary disease (COPD).You are currently taking medications like Cogentin, Chantix, Wellbutrin, Zyban, or any nicotine replacement products.You have a history of heart problems like heart attack, heart failure, chest pain, or irregular heartbeats.You have a neurological condition like a stroke, seizures, a disease that affects the brain, or a condition that causes brain problems.You smoke at least 10 cigarettes or cigarillos every day for at least 2 years.
Research Study Groups:
This trial has the following groups:- Group 1: Smokers without schizophrenia
- Group 2: Smokers with schizophrenia
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger